Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report report published on Sunday morning. The firm issued a sell rating on the stock.

A number of other research firms have also weighed in on CANF. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday, December 31st.

Can-Fite BioPharma Stock Performance

Shares of CANF opened at $1.56 on Friday. The firm has a market cap of $5.52 million, a PE ratio of -0.87 and a beta of 1.36. The company’s 50 day simple moving average is $1.66 and its 200-day simple moving average is $2.20. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.